1
|
Vinciguerra G, Belcaro G, Feragalli B, Cesarone MR, Rotondi V, Ledda A, Zuccarini M, Hosoi M, Dugall M, Cacchio M, Cornelli U. PycnoRacer®, a fitness drink including Pycnogenol®, improves recovery and training in the Cooper test. Panminerva Med 2020; 61:457-463. [PMID: 32043843 DOI: 10.23736/s0031-0808.19.03639-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND This study evaluates the effects of training (on running distance measured with a Cooper test) in 3 weeks in non-professional athletes using PycnoRacer®, a fitness drink (FD) including Pycnogenol® during the training period. METHODS Pycnogenol® has been used in preclinical conditions and prevention. PycnoRacer® is a liquid combination of Pycnogenol® (15 mg), L-leucine (0.6 g), L-arginine (0.3 g), L-isoleucine (0.3 g), and L-valine (0.3 g). Two comparable groups (one using the FD) were formed: 60 training athletes were requested to drink one bottle 4 times/day, while 65 controls did not use PycnoRacer® or other comparable sports drinks. All subjects had a strong athletic background and advanced knowledge of the procedures of the tests. Two daily training sessions were completed. The sessions consisted in warming up and running a Cooper test. RESULTS 125 subjects completed the three weeks according to plans. There were nine dropouts due to logistical or working problems. Subjects using the FD improved on average by 18.83% (range 12-23%) in their running distance with training. The difference with controls was significant (P<0.05) at 3 weeks (controls improved on average by 8.9%; range 3-17.4%). The difference between the two groups was on average 9.93% (P<0.05). A comparable increase in VO2max was observed in the groups. In the FD group the increase was on average by 10.05 mL/kg/min compared to 4.95 mL/kg/min in controls, with a difference of 5.1 mL/kg/min (P<0.05). A VAS score showed comparable values. Lower values (concerning muscular pain and cramps) were observed in FD subjects (P<0.05) at the end of the 3 weeks of training. The level of plasma free radicals (PFR) values after the last Cooper test was significantly lower at 3 weeks in the FD group (P<0.05). No intolerance problem was observed by subjects using the FD. CONCLUSIONS In conclusion, the use of PycnoRacer® improved training, running distance, VO2max and PFR decreasing muscular pain and cramps.
Collapse
Affiliation(s)
- Giulia Vinciguerra
- Department of Medical and Oral Sciences, and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Pescara, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy.,Department of Clinical, Oral, and Biotechnological Sciences, and Physiology, University of Chieti-Pescara, Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Pescara, Italy.,Department of Clinical, Oral, and Biotechnological Sciences, and Physiology, University of Chieti-Pescara, Pescara, Italy
| | - Maria Rosaria Cesarone
- IRVINE3 Labs, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Valentina Rotondi
- Department of Medical and Oral Sciences, and Biotechnologies, University of L'Aquila, L'Aquila, Italy
| | - Andrea Ledda
- IRVINE3 Labs, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | | | - Morio Hosoi
- IRVINE3 Labs, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Mark Dugall
- IRVINE3 Labs, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Marisa Cacchio
- Department of Clinical, Oral, and Biotechnological Sciences, and Physiology, University of Chieti-Pescara, Pescara, Italy
| | - Umberto Cornelli
- IRVINE3 Labs, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| |
Collapse
|
2
|
Belcaro G, Hu S, Strong J, Feragalli B, Vinciguerra G, Cacchio M, Cesarone MR. G3 sports supplement in short triathlon: improvements in training, performance, recovery and oxidative stress. Minerva Med 2018; 109:451-456. [DOI: 10.23736/s0026-4806.18.05757-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
3
|
Ledda A, Belcaro G, Feragalli B, Hosoi M, Cacchio M, Luzzi R, Dugall M, Cotellese R. Temporary kidney dysfunction: supplementation with Meriva® in initial, transient kidney micro-macro albuminuria. Panminerva Med 2018; 61:444-448. [PMID: 30486617 DOI: 10.23736/s0031-0808.18.03575-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The aim of this registry was to evaluate the efficacy of Meriva® in subjects with temporary kidney dysfunction (TKD) and increased oxidative stress levels. TKD was a casual finding on urinary tests after reported side effects following drug consumption, a clinical event or dehydration. METHODS Patients followed either standard management (SM) or SM plus Meriva® (Curcumin Phytosome®) supplementation (3 capsules/day, corresponding to 1.5 g of Meriva® containing 300 mg of curcumin in a bioavailable delivery form). The follow-up period lasted 4 weeks. Subjects were divided according to macroalbuminuria (>300 mg albumin on 24 hours) or microalbuminuria (<300 mg/day albuminuria). RESULTS Albuminuria decreased in all subjects, with a statistically significant improvement in the supplement group compared with controls (P<0.05). Oxidative stress level was high in all microalbuminuria subjects at inclusion; it was significantly more reduced in the supplement group (P<0.05) after 4 weeks. During follow-up blood pressure values were controlled; all subjects were under one single antihypertensive. Blood and urinary tests at 4 weeks were normalized in all subjects. Fatigue was significantly decreased or disappeared in most supplemented subjects at 4 weeks, with better results than in controls. Compliance and tolerability to Meriva® were good. CONCLUSIONS This registry study indicates that albuminuria - marker of TKD - is safely ameliorated with the standardized supplement Meriva®. Studies are needed to evaluate the effect of Meriva® in subjects with more significant clinical conditions (i.e. diabetics) or risk factors.
Collapse
Affiliation(s)
- Andrea Ledda
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Gianni Belcaro
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy - .,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Beatrice Feragalli
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Morio Hosoi
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Marisa Cacchio
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Roberta Luzzi
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Mark Dugall
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Roberto Cotellese
- Department of Medical and Oral Sciences and Biotechnology, Irvine3 Labs, University of Chieti-Pescara, Pescara, Italy.,International Agency For The Evaluation of Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| |
Collapse
|
4
|
Belcaro G, Gizzi G, Pellegrini L, Feragalli B, Cotellese R, Cacchio M, Corsi M. Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms. Panminerva Med 2018; 60:65-69. [PMID: 29737150 DOI: 10.23736/s0031-0808.18.03419-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this registry was to evaluate the effects of Pycnogenol® on the main symptoms of irritable bowel syndrome (IBS) in otherwise healthy individuals. METHODS This study included 77 healthy individuals with symptoms of IBS. The patients were divided into three groups: group 1 was treated with Buscopan (10 mg when needed), group 2 (Antispasmina col forte; 50 mg papaverine hydrochloride+10 mg belladonna extract when needed) and 3 (Pycnogenol® 150 mg/day) for 3 weeks. RESULTS The number of painful attacks was comparable in all groups after four weeks. Mild pain on manual abdomen pressure was decreased in all groups, with the improvement in the Pycnogenol® group significantly more pronounced that in both control groups (P<0.05). Perceived abdominal bowel movements/distension were significantly relieved in group 2 (Antispasmina Col Forte) and 3 (Pycnogenol®) (P<0.05) in comparison with Buscopan (group 1). CONCLUSIONS Pycnogenol® has shown a significant, protective and preventive activity on IBS symptoms, and thus it may represent a potential "soft" approach to IBS.
Collapse
Affiliation(s)
- Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy -
| | - Giuseppe Gizzi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Luciano Pellegrini
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Marisa Cacchio
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Marcello Corsi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
5
|
Cesarone MR, Belcaro G, Rulo A, Griffin M, Ricci A, Ippolito E, De Sanctis MT, Incandela L, Bavera P, Cacchio M, Bucci M. Microcirculatory Effects of Total Triterpenic Fraction of Centella asiatica in Chronic Venous Hypertension: Measurement by Laser Doppler, TcPo2-co2, and Leg Volumetry. Angiology 2018. [DOI: 10.1177/000331970105202s09] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this prospective, randomized study was to demonstrate whether an oral preparation of TTFCA was effective in improving the microcirculation and edema (leg volume) in venous microangiopathy. Forty patients with venous hypertension were included. Treatment was prescribed for 6 weeks (tablets, 60 mg twice daily). Patients were randomized into a treatment and a placebo group. There were 20 patients in each group. In the treatment group the mean age was 42 (SD 7; M:F = 10:10); in the placebo group, the mean age was 40 (SD 9; M:F = 10:10). Tolerability and compliance were very good; there were no dropouts. At inclusion there were no differences between placebo and treatment group. After treatment there was a decrease in resting flux (29%) and an improvement (increase) in venoarteriolar response (52%); PO2 was increased (7.2%) and PCO2 decreased (9.6%). There was an important decrease in leg volume (66 mL decrease; 1.3% volume variation). The difference in flux, O2-CO2 and volume parameters were significant and clinically important at 6 weeks in the treatment group. In conclusion, TTFCA improves microcirculation and leg volume in venous hypertension. The effects of TTFCA are observed even in a limited sample of patients.
Collapse
Affiliation(s)
- M. R. Cesarone
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - G. Belcaro
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - A. Rulo
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - M. Griffin
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - A. Ricci
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - E. Ippolito
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - M. T. De Sanctis
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - L. Incandela
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - P. Bavera
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - M. Cacchio
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| | - M. Bucci
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, General Surgery, Pescara, Physiology Chieti University, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College and Vascular Unit, Ealing Hospital, London, UK
| |
Collapse
|
6
|
Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG, Bucci M, Belcaro G. Total Triterpenic Fraction of Centella asiatica in Chronic Venous Insufficiency and in High-Perfusion Microangiopathy. Angiology 2018. [DOI: 10.1177/000331970105202s03] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Total triterpenic fraction of Centella asiatica (TTFCA) is effective in improving venous wall alterations in chronic venous hypertension and in protecting the venous endothelium. TTFCA is active on connective tissue modulation, improves the synthesis of collagen and other tissue proteins by modulating the action of fibroblasts in the vein wall, and stimulates collagen remodeling in and around the venous wall. This is due to the modulating action of TTFCA on fibroblasts as shown by experiments on the growth of human embryonal fibroblasts. TTFCA has a moderate in-vitro and in-vivo stimulating effect on collagen synthesis and, at higher dosages, an inhibition on the synthesis of collagen and acid mucopolysaccharides. Studies have indicated the role of TTFCA on the synthesis of specific venous wail elements by cell cultures of human embryonal fibroblasts. The tissue-stimulating action is shown by the increased collagen production independent from the stimulation of cell proliferation (this differentiates the action of TTFCA from cell growth factors). TTFCA is active on the microcirculation in venous and diabetic microangiopathy. Signs and symptoms of venous hypertension and edema are improved by treatment. The remodeling on collagen synthesis could be one of the possible mechanisms of actions of TTFCA in the remodeling of echolucent (soft; therefore, with risk of thrombosis and embolization) plaques at the carotid and femoral bifurcation. This compound is safe and well tolerated. In conclusion, several actions of TTFCA in vascular diseases makes the use of this compound very interesting in venous and arterial problems.
Collapse
Affiliation(s)
- L. Incandela
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - M. R. Cesarone
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - M. Cacchio
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - M. T. De Sanctis
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - C. Santavenere
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - M. G. D'Auro
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - M. Bucci
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| | - G. Belcaro
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino, Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital, London, UK
| |
Collapse
|
7
|
Belcaro G, Rulo A, Cesarone MR, De Sanctis MT, Incandela L, Griffin M, Cacchio M. Capillary Filtration in Venous Hypertension: Evaluation with the Vacuum Suction Chamber Device and Strain-Gauge Plethysmography. Angiology 2018. [DOI: 10.1177/000331970105202s08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aim of this study was to evaluate local capillary filtration with the vacuum suction chamber (VSC) and the rate of ankle swelling (RAS) in patients with ankle edema due to venous hypertension before and after treatment with oral TTFCA (60 mg tablets twice daily) for 4 weeks. Strain-gauge plethysmography (SGP) was used to assess RAS and local capillary filtration was studied with the VSC (applied on the perimalleolar region); the disappearance of the weal was measured (minutes). Fifty patients with chronic venous insufficiency and edema were included (M:F = 25:25) after informed consent and randomized into a treatment (mean age 43; SD 7) and a control (mean age 44; SD 8) group. Compliance was very good (100% completed the 4-week trial); no side effects were observed. The two groups were comparable for age/sex distribution. Values of RAS and VSC time were comparable in the two groups, at inclusion. After 4 weeks there were no changes in the control group. A significant reduction was observed in the treatment (RAS decreased to 34% of the initial value; the VSC time decreased 48%; p<0.02). Treatment with TTFCA in chronic venous insufficiency is useful as soon as edema is detected to control the progressive alterations leading to ulcerations. This action is produced by complex actions on the microcirculation reducing and controlling edema and modulating collagen synthesis. This results in an improvement of the microcirculation, skin and subcutaneous tissue perfusion and functions.
Collapse
Affiliation(s)
- G. Belcaro
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - A. Rulo
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - M. R. Cesarone
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - M. T. De Sanctis
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - L. Incandela
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - M. Griffin
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - M. Cacchio
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| |
Collapse
|
8
|
Cesarone MR, Belcaro G, De Sanctis MT, Incandela L, Cacchio M, Bavera P, Ippolito E, Bucci M, Griffin M, Geroulakos G, Dugall M, Buccella S, Kleyweght S, Cacchio M. Effects of the Total Triterpenic Fraction of Centella asiatica in Venous Hypertensive Microangiopathy: A Prospective, Placebo-Controlled, Randomized Trial. Angiology 2018. [DOI: 10.1177/000331970105202s04] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The aim of this study was to demonstrate whether total triterpenic fraction of Centella asiatica (TTFCA), was effective in improving the microcirculation in venous hypertension and microangiopathy. Forty patients with severe venous hypertension, ankle swelling, lipodermatosclerosis were included, After informed consent, patients were randomized into a treatment and a placebo group: those in the treatment group received TTFCA (tablets, 60 mg, twice daily for 8 weeks). The two groups of subjects were comparable for age and sex distribution. The mean age was 48 years (SD 9; M:F = 11:11) in the treatment group (22 patients) and 47.6 (SD 7; M:F = 10:8) in the placebo group (18 patients). There were no differences between placebo and treatment group at inclusion; there was no change between inclusion and measurements at 8 weeks in the placebo group. A decrease (p<0.05) in RF (flux at rest) and RAS (rate of ankle swelling) were observed in the treatment group. The decrease in capillary filtration was associated with improvement in signs and symptoms (p<0.05). The difference in flux, signs and symptoms, and filtration was clinically important at 8 weeks. No side effects were observed. In conclusion venous microangiopathy was improved by TTFCA treatment.
Collapse
Affiliation(s)
- M. R. Cesarone
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - G. Belcaro
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. T. De Sanctis
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - L. Incandela
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. Cacchio
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - P. Bavera
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - E. Ippolito
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. Bucci
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. Griffin
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - G. Geroulakos
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. Dugall
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - S. Buccella
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - S. Kleyweght
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| | - M. Cacchio
- Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Vascular Surgery, University of Milan, Italy
- Irvine Vascular Laboratory, St Mary's Hospital and Imperial College, Vascular Unit, Ealing Hospital, London, UK
| |
Collapse
|
9
|
Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M, Cacchio M. Methods of Evaluation and Quantification of Microangiopathy in High Perfusion Microangiopathy (Chronic Venous Insufficiency and Diabetic Microangiopathy). Angiology 2018. [DOI: 10.1177/000331970105202s02] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Noninvasive tests have been developed to provide qualitative and quantitative information that can offer answers to most questions posed in venous diseases. While duplex scanning is used to assess the macrocirculation, microcirculatory methods assess and quantify venous microangiopathy. Laser Doppler flowmetry is used to assess tissue viability and perfusion. Transcutaneous PO2 and PCO2 measurements are used to study venous hypertension, and strain-gauge plethysmography (SGP) is used to assess capillary filtration. In venous hypertension fluid filtration into the extracapillary compartment is increased. The increase in filtration is associated with a decreased venoarteriolar response. To quantify capillary filtration two methods have been developed: venous occlusion plethysmography and rate of ankle swelling. These methods quantify filtration into the extracapillary compartment and therefore are an indication of the formation of edema, which is the most frequent sign of venous hypertension. Other methods such as the vacuum suction chamber and the edema tester can be used to assess changes due to treatment in chronic venous hypertension. These methods have been used and validated in several experimental and clinical studies. The techniques described in this article were used in controlled environmental conditions. Results were consistent with clinical problems and data from previous studies from our group and from data from other investigators.
Collapse
Affiliation(s)
- M. R. Cesarone
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
| | - M. T. De Sanctis
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
| | - L. Incandela
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
| | - G. Belcaro
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
| | - M. Griffin
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| | - M. Cacchio
- From the Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Italy
- Vascular Unit, Ealing Hospital and Irvine Laboratory, St Mary's Hospital at Imperial College, London, UK
| |
Collapse
|
10
|
Riva A, Vitale JA, Belcaro G, Hu S, Feragalli B, Vinciguerra G, Cacchio M, Bonanni E, Giacomelli L, Eggenhöffner R, Togni S. Quercetin phytosome® in triathlon athletes: a pilot registry study. Minerva Med 2018; 109:285-289. [DOI: 10.23736/s0026-4806.18.05681-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
11
|
Ledda A, Belcaro G, Feragalli B, Hosoi M, Cacchio M, Luzzi R, Dugall M, Cotellese R, Cesarone MR. Temporary kidney dysfunction: Robuvit® supplementation in initial, transient kidney insufficiency and micro-macro albuminuria. Panminerva Med 2018; 60:60-64. [DOI: 10.23736/s0031-0808.18.03420-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
12
|
Falone S, Santini S, Cordone V, Di Emidio G, Tatone C, Cacchio M, Amicarelli F. Extremely Low-Frequency Magnetic Fields and Redox-Responsive Pathways Linked to Cancer Drug Resistance: Insights from Co-Exposure-Based In Vitro Studies. Front Public Health 2018. [PMID: 29527520 PMCID: PMC5829633 DOI: 10.3389/fpubh.2018.00033] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Electrical devices currently used in clinical practice and common household equipments generate extremely low-frequency magnetic fields (ELF-MF) that were classified by the International Agency for Research on Cancer as “possible carcinogenic.” Assuming that ELF-MF plays a role in the carcinogenic process without inducing direct genomic alterations, ELF-MF may be involved in the promotion or progression of cancers. In particular, ELF-MF-induced responses are suspected to activate redox-responsive intracellular signaling or detoxification scavenging systems. In fact, improved protection against oxidative stress and redox-active xenobiotics is thought to provide critical proliferative and survival advantage in tumors. On this basis, an ever-growing research activity worldwide is attempting to establish whether tumor cells may develop multidrug resistance through the activation of essential cytoprotective networks in the presence of ELF fields, and how this might trigger relevant changes in tumor phenotype. This review builds a framework around how the activity of redox-responsive mediators may be controlled by co-exposure to ELF-MF and reactive oxygen species-generating agents in tumor and cancer cells, in order to clarify whether and how such potential molecular targets could help to minimize or neutralize the functional interaction between ELF-MF and malignancies.
Collapse
Affiliation(s)
- Stefano Falone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Silvano Santini
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Valeria Cordone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Giovanna Di Emidio
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Carla Tatone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Marisa Cacchio
- Department of Neurosciences, Imaging and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy
| | - Fernanda Amicarelli
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.,Institute of Translational Pharmacology (IFT)-National Research Council (CNR), L'Aquila, Italy
| |
Collapse
|
13
|
Feragalli B, Ippolito E, Dugall M, Cacchio M, Belcaro G, Cesarone MR, Abdel-Tawab M, Riva A, Togni S, Eggenhoffner R, Giacomelli L. Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma - a registry study. Eur Rev Med Pharmacol Sci 2017; 21:4726-4732. [PMID: 29131239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE In this study, we evaluated a novel delivery form of boswellic acids (Casperome®) in the management of signs and symptoms associated with ankle sprain grade II due to sport trauma. PATIENTS AND METHODS In this supplement registry study, 72 otherwise healthy subjects with grade II ankle sprain induced by sport activities were advised to either follow a standard management (SM, 37 subjects) for the condition or the SM with the additional daily intake of 1 tablet containing 250 mg Casperome® (35 subjects). Subjects were allowed to use rescue medications (ketoprofen tablets, 25 mg/tablet), and their intake was measured at the end of the management period of 7 days. Each individual was subjected to several non-invasive examinations (self-reported pain at rest and under moderate exercise, range of active and passive movement, presence of local hematomas by ultrasonography) at the following time periods: at inclusion, to evaluate the basal conditions of the subject before the beginning of the study, at day 3 and at the end of the week to evaluate the response differences between the two groups. Additionally, a blood sample from the Casperome® treated subjects (34 out of 35 subjects) was taken at day 7 and analyzed for the systemic concentration of boswellic acids. RESULTS The 72 individuals recruited in this study spontaneously decided which management to follow, either SM (n=37) or SM+Casperome® (n=35). Supplementation with Casperome® 250 mg/day showed beneficial effects in the reduction of signs and symptoms of ankle sprains evaluated at day 3 and day 7, and was shown to induce measurable plasma level of boswellic acids. Moreover, the supplementary use of Casperome® was well-tolerated and devoid of side effects. CONCLUSIONS Our pilot registry study showed the effectiveness of Casperome® supplementation in improving recovery after ankle sprain of mild severity (grade II), suggesting a potentially beneficial role in relieving the trauma associated with sport activities and in decreasing the use of rescue drugs.
Collapse
Affiliation(s)
- B Feragalli
- IRVINE3 Vascular Lab and Physiology, Chieti - Pescara University.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Falone S, Santini S, Cordone V, Cesare P, Bonfigli A, Grannonico M, Di Emidio G, Tatone C, Cacchio M, Amicarelli F. Power frequency magnetic field promotes a more malignant phenotype in neuroblastoma cells via redox-related mechanisms. Sci Rep 2017; 7:11470. [PMID: 28904402 PMCID: PMC5597619 DOI: 10.1038/s41598-017-11869-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Accepted: 08/29/2017] [Indexed: 12/27/2022] Open
Abstract
In accordance with the classification of the International Agency for Research on Cancer, extremely low frequency magnetic fields (ELF-MF) are suspected to promote malignant progression by providing survival advantage to cancer cells through the activation of critical cytoprotective pathways. Among these, the major antioxidative and detoxification defence systems might be targeted by ELF-MF by conferring cells significant resistance against clinically-relevant cytotoxic agents. We investigated whether the hyperproliferation that is induced in SH-SY5Y human neuroblastoma cells by a 50 Hz, 1 mT ELF magnetic field was supported by improved defence towards reactive oxygen species (ROS) and xenobiotics, as well as by reduced vulnerability against both H2O2 and anti-tumor ROS-generating drug doxorubicin. ELF-MF induced a proliferative and survival advantage by activating key redox-responsive antioxidative and detoxification cytoprotective pathways that are associated with a more aggressive behavior of neuroblastoma cells. This was coupled with the upregulation of the major sirtuins, as well as with increased signaling activity of the erythroid 2-related nuclear transcription factor 2 (NRF2). Interestingly, we also showed that the exposure to 50 Hz MF as low as 100 µT may still be able to alter behavior and responses of cancer cells to clinically-relevant drugs.
Collapse
Affiliation(s)
- S Falone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
| | - S Santini
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - V Cordone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - P Cesare
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - A Bonfigli
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - M Grannonico
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - G Di Emidio
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - C Tatone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - M Cacchio
- Department of Neurosciences, Imaging and Clinical Sciences, University "G. d'Annunzio", Chieti Scalo (CH), Italy
| | - F Amicarelli
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.,Institute of Translational Pharmacology (IFT) - CNR, L'Aquila, Italy
| |
Collapse
|
15
|
Belcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M, Feragalli B, Togni S, Riva A, Eggenhoffner R, Giacomelli L. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2017; 21:2249-2254. [PMID: 28537656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE Irritable Bowel Syndrome (IBS) is a chronic, gastrointestinal disorder in which abdominal pain or discomfort is associated with defecation or changes in bowel habits. Its multifactorial pathophysiology leads to a variety of available treatments, mainly aimed at controlling symptoms. The management of IBS patients could be optimized by individualized strategies, including non-pharmaceutical approaches. In this study, we evaluated the efficacy and safety of a novel delivery form of Boswellia serrata extracts (BSE) (Casperome®) in patients with IBS. PATIENTS AND METHODS 71 otherwise healthy subjects with idiopathic IBS were recruited. Participants were assigned to the following management strategies: hyoscine butylbromide; papaverine hydrochloride + A. belladonna extract; supplementation with Casperome®. Predominant IBS symptoms were evaluated at inclusion and at the end of the observational period (4 weeks). The numbers of subjects who needed rescue medication or medical attention/hospital admission were recorded. Adverse events were also evaluated. RESULTS In all groups, the IBS symptoms investigated, namely abdominal pain, altered bowel movements, meteorism and cramps improved during the observational period. Of note, the number of subjects who needed medical attention significantly decreased only in Casperome®-supplemented group. In addition, Casperome® supplementation was related to a lower incidence of side effects (mainly stypsis). CONCLUSIONS This preliminary study suggests that Casperome® supplementation could represent a promising alternative approach to manage symptoms associated with IBS in otherwise healthy subjects.
Collapse
Affiliation(s)
- G Belcaro
- Irvine 3 Circulation/Vascular Labs, Chieti-Pescara University, Pescara, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Riva A, Togni S, Giacomelli L, Franceschi F, Eggenhoffner R, Feragalli B, Belcaro G, Cacchio M, Shu H, Dugall M. Effects of a curcumin-based supplementation in asymptomatic subjects with low bone density: a preliminary 24-week supplement study. Eur Rev Med Pharmacol Sci 2017; 21:1684-1689. [PMID: 28429336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE Osteopenia is a chronic bone condition characterized by decreased calcification, density, or bone mass that, if untreated, can lead to osteoporosis and bone fractures. Although its increasing prevalence, nowadays osteopenia is not adequately prevented and managed. In this study, we evaluated the efficacy, in term of changes in bone density, and safety of an oral formulation based on turmeric phytosome (Meriva®), in subjects suffering from low bone density. PATIENTS AND METHODS 57 otherwise healthy subjects with low bone density were enrolled in this pilot, supplement study. Informed participants freely decided to follow either a standard management (SM) to control low bone density (control group=28) or SM associated with a curcumin-based oral supplementation (supplement group=29). The bone densities of heel, small finger and upper jaw were evaluated at inclusion and at different time points during the observational period (4, 12 and 24 weeks), in all subjects. RESULTS The bone density of the heel measured by the Sahara densitometer remarkably improved in the Meriva®-supplemented group, with a significant decrease of ultrasounds transmission values at week 12 (-18.4%) and at week 24 (-21.0%), compared with baseline values. The bone densities of small finger and upper jaw also significantly increased during the study in supplemented subjects, reaching +7.1% and +4.8%, respectively, at week 24, with respect to values at inclusion. Noteworthy, no significant changes of heel, small finger and upper jaw densities were observed in the control group. Last, no safety and tolerability issues were reported during the observational period. CONCLUSIONS This preliminary study suggests that a curcumin-based supplementation in combination with an appropriate lifestyle could be beneficial in the prevention and management of osteopenia.
Collapse
Affiliation(s)
- A Riva
- Indena SpA, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Belcaro G, Cesarone MR, Corsi M, Errichi BM, Cornelli U, Ippolito E, Errichi S, Di Renzo A, Ledda A, Cacchio M, Bottari A, Grossi MG. Superficial Vein Thrombosis (SVT), Diffusion of Thrombotic Diseases, and Increased Global Thrombogenicity: SVT as an Important Spy Disease Indicating Environmental Contamination by Estrogens: Introduction. Angiology 2016; 58 Suppl 1:5S-6S. [PMID: 17478876 DOI: 10.1177/0003319706298408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Gianni Belcaro
- Department of Biomedical Science, G. D'Annunzio University, Pescara, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Cesarone MR, Belcaro G, Agus G, Georgiev M, Errichi BM, Marinucci R, Errichi S, Filippini A, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Cipollone G, Lania M, Gizzi G, Ippolito E, Bavera P, Fano F, Dugall M, Adovasio R, Gallione L, Del Boccio G, Cornelli U, Steigerwalt R, Acerbi G, Cacchio M, Di Renzo A, Hosoi M, Stuard S, Corsi M, Di Ciano L, Simeone E, Collevecchio G, Grossi MG, Di Giambattista F, Carestia F, Zukowski A. Management of Superficial Vein Thrombosis and Thrombophlebitis: Status and Expert Opinion Document. Angiology 2016; 58 Suppl 1:7S-14S; discussion 14S-15S. [PMID: 17478877 DOI: 10.1177/0003319706297643] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Superficial vein thrombosis is characterized by clotting of superficial veins (ie, following direct trauma) with minimal inflammatory components. Superficial thrombophlebitis is a minimally thrombotic process of superficial veins associated with inflammatory changes and/or infection. Treatments generally include analgesics, elastic compression, anti-inflammatory agents, exercise and ambulation, and, in some cases, local or systemic anticoagulants. It is better to avoid bed rest and reduced mobility. Topical analgesia with nonsteroidal, anti-inflammatory creams applied locally to the superficial vein thrombosis/superficial thrombophlebitis area controls symptoms. Hirudoid cream (heparinoid) shortens the duration of signs/symptoms. Locally acting anticoagulants/antithrombotics (Viatromb®, Lipohep ®, spray Na-heparin) have positive effects on pain and on the reduction in thrombus size. Intravenous catheters should be changed every 24 to 48 hours (depending on venous flow and clinical parameters) to prevent superficial vein thrombosis/superficial thrombophlebitis and removed in case of events. Low molecular weight heparin prophylaxis and nitroglycerin patches distal to peripheral lines may reduce the incidence of superficial vein thrombosis/superficial thrombophlebitis in patients with vein catheters. In case of superficial vein thrombosis/superficial thrombophlebitis, vein lines should be removed. In neoplastic diseases and hematological disorders, anticoagulants may be necessary. Exercise reduces pain and the possibility of deep vein thrombosis. Only in cases in which pain is very severe is bed rest necessary. Deep vein thrombosis prophylaxis should be established in patients with reduced mobility. Antibiotics usually do not have a place in superficial vein thrombosis/superficial thrombophlebitis unless there are documented infections. Prevention of superficial vein thrombosis should be considered on the basis of patient's history and clinical evaluation.
Collapse
Affiliation(s)
- M R Cesarone
- Vascular Lab, Department of Biomedical Science, G D'Annunzio University, Pescara; San Valentino Vascular Screening Project, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Belcaro G, Cesarone MR, Dugall M, Di Renzo A, Errichi BM, Cacchio M, Ricci A, Stuard S, Ippolito E, Fano F, Theng A, Kasai M, Hakim G, Acerbi G. Effects of Shock Waves on Microcirculation, Perfusion, and Pain Management in Critical Limb Ischemia. Angiology 2016; 56:403-7. [PMID: 16079923 DOI: 10.1177/000331970505600407] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Shock waves (SW) are used to control pain in different clinical conditions (eg, painful knee, elbow, and shoulder, etc). The effects of SWs may be due to cellular “stunning” (particularly nervous components). It may also be the consequence of unknown metabolic actions on tissues, which may include changes in cellular permeability, the liberation of proteins and mediators locally acting on pain and nerve endings. The aim of this study was to evaluate the reduction in pain and the improvement in microcirculation induced by SW treatment in a 2-week study in patients with chronic limb ischemia (CLI). Of the 32 patients with CLI, 30 (20 with rest pain only, 10 with necrosis) completed the study. The treatment was well tolerated. Foot radiographs performed before and after treatment indicate no bone damage after treatment. Foot (tibial arteries) blood pressure was unchanged after 2 weeks. The increase in laser Doppler flux was significant (p<0.05) after treatment. The ORACLE score at 2 weeks was decreased (p<0.05). The same trend was observed with the analogue scale line for pain (p<0.05). Partial pressure of oxygen (PO2) increased (p<0.05) and partial pressure of carbon dioxide (PCO2) decreased (p<0.05). In all patients an increase in pain-free walking distance was observed (the distance increased on average 2.4 times). Flux improvement was still present after 1 month. The outcome at 3 months in these patients indicates that the improvement (concerning the survival of the limbs) was persistent. In conclusion SWs treatment in CLI produced changes both on the microcirculation and pain. These results are very interesting, confirming previous observations, and opening new treatment options in CLI. The skin flow improvement did not relate to an increase in pressure.
Collapse
Affiliation(s)
- G Belcaro
- Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti-Pescara University, San Valentino Vascular Screening Center, San Valentino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Belcaro G, Cesarone MR, Errichi BM, Di Renzo A, Errichi S, Ricci A, Gizzi G, Dugall M, Cacchio M, Ruffini I, Fano F, Vinciguerra G, Grossi MG. Improvement of Microcirculation and Healing of Venous Hypertension and Ulcers With Crystacide ®: Evaluation With a Microcirculatory Model, Including Free Radicals, Laser Doppler Flux, and PO2/PCO2 Measurements. Angiology 2016; 58:323-8. [PMID: 17626987 DOI: 10.1177/0003319707301450] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In 32 patients with chronic venous insufficiency and venous hypertension associated with ulcerations, the effects of the local application of a hydrogen peroxide cream (Crystacide) applied onto the skin was evaluated using a complex, proportional, microcirculatory model to assess and quantify venous microangiopathy after local treatment. A comparative group treated without Crystacide was included. Laser Doppler flowmetry was used to assess skin perfusion (flux and venoarteriolar response) in association with transcutaneous PO2 and PCO2 measurements. Local plasma free radicals were evaluated in the area surrounding the venous ulcer using the D-Roms test. Crystacide was applied around and on the ulcer for 10 days. Crystacide was more effective than the control treatments. PO2 was increased (improved, P < .05), and plasma free radicals, PCO2, and laser Doppler flowmetry were decreased (improving toward normal values, P < .05). Also, the ulcerated area was significantly smaller at 10 days in the Crystacide group in comparison with controls (P < .05). In the proportional microcirculatory model, all parameters indicated an important level of improvement significantly larger than in controls. In conclusion, in chronic venous insufficiency and venous ulcerations, local treatment with Crystacide (10 days) improves the microcirculation and decreases skin free radicals, thus improving healing.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, PE, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cacchio M, Di Renzo A, Stuard S, Corsi M. HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton®): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study. Angiology 2016; 56:165-72. [PMID: 15793606 DOI: 10.1177/000331970505600207] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this independent study was to demonstrate the rapidity of the clinical action of HR 0-(beta-hydroxyethyl)-rutosides, Venoruton® (Novartis Consumer Health) in patients with chronic venous insufficiency (CVI). Two groups of patients with venous hypertension and microangiopathy were treated with HR (1 or 2 g/day, for 8 weeks). Twelve patients (age 56.4; range 44-66; M:F = 6:6) were included in group 1 (1 g/day) (moderate CVI and microangiopathy); 10 patients (age 57.4; range 42-67; M:F = 5:5) in group 2 (2 g/day) with more severe CVI and microangiopathy. Average ambulatory venous pressure (AVP) was 58.6 (range 50-65) with a refilling time (RT) shorter than 10 seconds. There were no significant differences in AVP and RT between the 2 groups, but the duration of the disease was longer in group 2: 3.5 years (SD 2.0) in group 1 and 6.4 years (SD 3.3) in group 2. All included subjects completed the study and no dropouts were observed. In both dose groups there was a progressive decrease in laser Doppler resting flux (RF), indicating improvement in microangiopathy and a significant decrease in capillary filtration (RAS) associated with a significant improvement in analogue scale line score (ASLS) and edema. Although the effect in the 2 g dose group was more rapid on the microcirculatory parameters with a significant effect on RF and RAS after 4 days (effect of 1 g per day after 8 days and 6 days, respectively), there was no difference in the time to onset of a significant clinical improvement (ie, the ASLS and the edema score): 4 days in both groups. Venous microangiopathy and edema were improved by the treatment with HR within a few days. The effects were visible with both dosages, in both severity groups.
Collapse
Affiliation(s)
- M R Cesarone
- Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G. D'Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, San Valentino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Di Renzo A, Vinciguerra G, Ricci A, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cacchio M. HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study. Angiology 2016; 56:1-8. [PMID: 15678250 DOI: 10.1177/000331970505600101] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aim of this independent study was to investigate differences in efficacy between HR, (0-[beta-hydroxyethyl]-rutosides) and D+H (500 mg, diosmin+hesperidin) in patients with chronic venous insufficiency (CVI). A first group of 90 patients with severe venous hypertension (CVI, ankle swelling) were randomized into an HR or a D+H group. The HR group received oral HR (2 g/day, 8 weeks); the D+H group received a 500 mg tablet 3 times daily for 8 weeks. A second group of comparable patients was included in a registry following the same study format. Patients were openly included; the 2 treatments were administered with the same methods and procedures. Clinical conditions were comparable to those described in the randomized study. Patients treated for at least 8 weeks were included in the registry. A number of physicians (specialists or general practitioners) included patients when they considered that clinical conditions were compatible with using 1 of the 2 treatments on the basis of their personal evaluation and experience. When cases were compatible with the registry, the prescribing physician communicated the case. Patients were evaluated without interfering with the treatment. Main targets of evaluation were skin flux at rest (RF), strain-gauge-derived rate of ankle swelling (RAS), and analogue symptoms score (ASLS). Ninety subjects completed the study in the first group; 122 in the second, registry group (total of 212 patients). The first and second (registry) groups and the 2 treatment groups were comparable for age and sex distribution. The pooled mean age was 42 years (SD ±5.5) in the HR group (46+62 patients) and 41.5 (SD ±6) in the D+H group (44+60 patients). Considering pooled data there were no differences in microcirculatory parameters between the pooled treatment groups at inclusion. A significant decrease (p<0.05) in RF and RAS was observed in the HR group at 8 weeks. The decrease in resting skin flux and in capillary filtration was associated with a significant improvement in signs/symptoms (analogue scale line) from an average of 9.4 (range 3-10) to 3.3 (4-6) (p<0.05). Significantly smaller variations were observed in the D+H group. The decrease in RF was 47.6% in the HR group vs 15.7% in the D+H group. The decrease in RAS was 40.9% in the HR group vs 12.8% in the D+H group. The decrease in ASLS was 64.8% in the HR group vs 12.9% in the comparative group. In conclusion venous microangiopathy and edema were improved by the treatment with HR both in the randomized study and in the pooled analysis. The comparison with D+H indicates that HR is comparatively more effective both on microcirculatory parameters and on signs/symptoms of CVI.
Collapse
Affiliation(s)
- M R Cesarone
- Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Cesarone MR, Belcaro G, Ricci A, Brandolini R, Pellegrini L, Dugall M, Di Renzo A, Vinciguerra G, Gizzi G, Cornelli U, Errichi BM, Corsi M, Ippolito E, Adovasio R, Cacchio M, Stuard S, Larnier C, Candiani C, Cerritelli F. Prevention of Edema and Flight Microangiopathy with Venoruton ® (HR), (0-[Beta-Hydroxyethyl]Rutosides) in Patients with Varicose Veins. Angiology 2016; 56:289-93. [PMID: 15889196 DOI: 10.1177/000331970505600308] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this open study was the evaluation of the effects of HR (Venoruton®) at a dose of 1 g/day on the prevention and control of flight microangiopathy and edema in subjects with varicose veins and moderate chronic venous insufficiency flying for more than 11 hours. Patients with varicose veins, edema, but without initial skin alterations or complications, were included. Measurements of skin laser Doppler (LDF) resting flux (RF) venoarteriolar response (VAR), ankle swelling (RAS), and edema were made within 12 hours before and within 3 hours after the flights. The resulting edema after the flights was evaluated with a composite edema score (analogue scale line). A group of 20 subjects was treated with HR (1 g/day, starting 2 days before the flight and 1 g for every 12 hours on day of travel). Another group of 18 subjects formed the control group. The length of the flights was between 11 and 13 hours; all seats were in coach class. Fifty patients were enrolled and 38 patients were evaluable at the end of the trial. The 2 groups (treatment and control) were comparable for age and sex distribution. The decrease in RF was significant in both groups with a higher flux at the end of the flight in the HR group (p<0.05). The venoarteriolar response was decreased at the end of the flights; the decrease was lower in the HR group (p<0.05). The increase in RAS and the edema score were significantly lower in the HR group. In conclusion HR is useful for reducing the level of microangiopathy and the increased capillary filtration and in controlling edema in patients with venous disease in long flights. The higher level of flux and VAR and the reduction in edema indicate a positive effect of HR on the microcirculation. This study confirms that HR prophylaxis is effective to control flight microangiopathy associated with edema.
Collapse
Affiliation(s)
- M R Cesarone
- Vascular Laboratory and San Valentino Vascular Screening Project, Department of Biomedical Sciences, G D'Annunzio University, Chieti-Pescara and Faculty of Motor Sciences, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ippolito E, Scoccianti M, Ricci A, Dugall M, Cacchio M, Ruffini I, Fano F, Acerbi G, Vinciguerra MG, Bavera P, Di Renzo A, Errichi BM, Mucci F. Prevention of Edema in Long Flights with Pycnogenol®. Clin Appl Thromb Hemost 2016; 11:289-94. [PMID: 16015414 DOI: 10.1177/107602960501100307] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aim of this study was to evaluate the prevention of edema during long-haul flights with an oral, anti-edema and antithrombotic agent (Pycnogenol®, Horphag, Research Management SA, Geneva, Switzerland) in asymptomatic subjects. The assessment of edema was performed by evaluating an analogue scale, the rate of ankle swelling by strain-gauge derived rate of ankle swelling (RAS), and by assessing the ankle circumference variation. The study included 211 subjects; 169 completed the study (88 in the control group and 81 in the Pycnogenol® group). There were no important differences between the two groups (comparable for age, gender, weight, body mass index, and pattern distribution). The edema score, the RAS, and the circumference at inclusion were also comparable. After the flight in those treated with Pycnogenol®, the edema score was increased only by 17.9% (vs. an increase of 58.3% in the control group) (p<0.05). The RAS, evaluated in 22 subjects in the Pycnogenol® group (age 44.5; SD 8) and in 23 in the control group (age 45; SD 9) was increased on average by 91% in the control group and 36% in the Pycnogenol® group (p<0.05). The variation on circumference at the ankle was 6% in the Pycnogenol® group (11% in the control group; p<0.05). These results indicate a positive effect of Pycnogenol® on edema during long flights when considering subjective and objective data. No unwanted effects were observed.
Collapse
Affiliation(s)
- M R Cesarone
- Department of Biomedical Sciences, Irvine2 Vascular Lab, G D'Annunzio University and San Valentino Vascular Screening Project (Pe), Faculty of Motory Sciences, L'Aquila University, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Gizzi G, Ippolito E, Fano F, Dugall M, Acerbi G, Cacchio M, Di Renzo A, Hosoi M, Stuard S, Corsi M. Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton. J Cardiovasc Pharmacol Ther 2016; 11:93-8. [PMID: 16703224 DOI: 10.1177/107424840601100109] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Damage to endothelial cells is common in vascular disorders and in reactions associated with transplantation. An elevated number of circulating endothelial cells indicates the extent of endothelial damage in a variety of disorders. In chronic venous insufficiency (CVI), the number of endothelial cells is abnormally increased, and this can be considered an important indication of endothelial damage. A group of 23 subjects with two levels of CVI (severe and very severe with previous ulcerations) with an increased endothelial cell count (seen by microscopy) was studied and treated for 4 weeks with oral Venoruton (0-[beta-hydroxyethyl]-rutosides) (1 g/day) to evaluate the effects of treatment on the circulating endothelial cells in blood taken from a peripheral leg vein. The controls comprised two groups with comparable age and sex distribution, one of healthy individuals and one of CVI subjects. After 4 weeks, a significant decrease was noted in endothelial cells both in subjects with CVI and in those with very severe CVI with previous ulcerations. This study suggests that endothelial cells may play a significant role in venous disease, being both an indication of severe disease and a further problem in itself. The use of Venoruton appears to decrease the number of circulating endothelial cells. This suggests an important role of this compound in protecting the endothelium and offers new potentially important therapeutic options that are not limited only to venous disease.
Collapse
Affiliation(s)
- Maria Rosaria Cesarone
- Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G D'Annunzio, University, Chieti-Pescara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Centurione L, Di Giulio C, Santavenere E, Cacchio M, Sabatini N, Rapino C, Bianchi G, Rapino M, Bosco D, Antonucci A, Cataldi A. Protein Kinase Cζ Regulation of Hypertrophic and Apoptotic Events Occurring during Rat Neonatal Heart Development and Growth. Int J Immunopathol Pharmacol 2016; 18:49-58. [PMID: 15698510 DOI: 10.1177/039463200501800106] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The development and growth of the rat heart implies hyperplasia, which stops at birth, and hypertrophy, allowing cardiac mass to grow in response to programmed genetic events along with to haemodynamic overload. Moreover, hypertrophy is accomplished to apoptosis which controls the final number of myocardial cells, deletes vestigial structures, and takes part in remodelling the organ. Since at the basis of all these processes, which lead to the complete development of the heart, the activation of specific signalling pathways underlies, attention has been addressed to the role played in vivo by Protein Kinase Cζ (PKCζ) in regulating NF-kB signalling system and “intrinsic” mitochondrial apoptotic route at days 1, 4, 10 and 22 of rat life. In fact, a role has been assigned to PKCζ in indirectly phosphorylating IKBα, which peaks between 10 and 22 days, through a IKK determining, in turn, NF-kB activation, concomitantly to cytochrome c/Apaf 1 co-localization in the cytoplasm and caspase-9/caspase-3 activation, which leads to the occurrence of apoptosis. Thus a key role for PKCζ in regulating the hypertrophic and apoptotic events leading to establishment of complete function in rat neonatal heart is here suggested.
Collapse
Affiliation(s)
- L Centurione
- Dipartimento di Biomorfologia, Facoltà di Farmacia, Cattedra di Anatomia Umana, University of Chieti, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Falone S, Santini S, di Loreto S, Cordone V, Grannonico M, Cesare P, Cacchio M, Amicarelli F. Improved Mitochondrial and Methylglyoxal-Related Metabolisms Support Hyperproliferation Induced by 50 Hz Magnetic Field in Neuroblastoma Cells. J Cell Physiol 2016; 231:2014-25. [PMID: 26757151 DOI: 10.1002/jcp.25310] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 01/08/2016] [Indexed: 12/27/2022]
Abstract
Extremely low frequency magnetic fields (ELF-MF) are common environmental agents that are suspected to promote later stages of tumorigenesis, especially in brain-derived malignancies. Even though ELF magnetic fields have been previously linked to increased proliferation in neuroblastoma cells, no previous work has studied whether ELF-MF exposure may change key biomolecular features, such as anti-glycative defence and energy re-programming, both of which are currently considered as crucial factors involved in the phenotype and progression of many malignancies. Our study investigated whether the hyperproliferation that is induced in SH-SY5Y human neuroblastoma cells by a 50 Hz, 1 mT ELF magnetic field is supported by an improved defense towards methylglyoxal (MG), which is an endogenous cancer-static and glycating α-oxoaldehyde, and by rewiring of energy metabolism. Our findings show that not only the ELF magnetic field interfered with the biology of neuron-derived malignant cells, by de-differentiating further the cellular phenotype and by increasing the proliferative activity, but also triggered cytoprotective mechanisms through the enhancement of the defense against MG, along with a more efficient management of metabolic energy, presumably to support the rapid cell outgrowth. Intriguingly, we also revealed that the MF-induced bioeffects took place after an initial imbalance of the cellular homeostasis, which most likely created a transient unstable milieu. The biochemical pathways and molecular targets revealed in this research could be exploited for future approaches aimed at limiting or suppressing the deleterious effects of ELF magnetic fields. J. Cell. Physiol. 231: 2014-2025, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Stefano Falone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Silvano Santini
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Silvia di Loreto
- Institute of Translational Pharmacology (IFT)-CNR, L'Aquila, Italy
| | - Valeria Cordone
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Marta Grannonico
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Patrizia Cesare
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - Marisa Cacchio
- Department of Biomedical Sciences, University "G. d'Annunzio", Via dei Vestini, Chieti Scalo (CH), Italy
| | - Fernanda Amicarelli
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.,Institute of Translational Pharmacology (IFT)-CNR, L'Aquila, Italy
| |
Collapse
|
28
|
Vinciguerra MG, Belcaro G, Cacchio M. Robuvit® and endurance in triathlon: improvements in training performance, recovery and oxidative stress. Minerva Cardioangiol 2015; 63:403-409. [PMID: 26488613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
AIM The aim of this registry study was to evaluate the effects of supplementation with Robuvit® (Quercus robur wood extract, or "QR") on performance and endurance in triathlon by evaluating amateur athletes in a period of 2 weeks of training. Supplementation with QR may improve training efficiency (by decreasing post-triathlon, muscular pain, cramps and by improving recovery time). Robuvit® should decrease post-training plasma free radicals (PFR). METHODS Sixty-one subjects (age range 30-40) were included in the study. Subjects followed a free diet. An isotonic saline drink was suggested to all subjects. RESULTS After 2 weeks there were 27 subjects using the supplement and 27 without supplementation. The groups were comparable. All subjects improved in training considering the 3 events (swim, biking, run). The improvement was greater with Robuvit® (P<0.05) for the swim and biking (P<0.05); the running time decreased by 12.32% in subjects using Robuvit® (3.6% in controls; P<0.05). The improvement the total triathlon time was -10.56% with Robuvit® in comparison to -3.41% in controls. SAFETY no side effects or tolerance problems were reported; all QR capsules were used as indicated. CONCLUSION In conclusion, the -10.56% shorter total trioathlon time was considered as very good improvement, considering that for this type of athletes being almost at the top of their form it is difficult to improve even further without severe training. Training was considered better (on an analogue scale) in the QR group (P<0.05). Postrun muscular pain, cramps, localized pain, straining and the recovery time, were all considered better with QR (P<0.05). Plasma free radical (PFR) values 1 hour after the final run were, on average,16.98% higher in controls (P<0.05), indicating a higher level of oxidative stress. Higher levels of PFR are associated with a slower recovery. All routine blood tests were normal at inclusion and after the final triathlon. After the final test run triathlon athletes using QR had a lower increase of UBR and LDH (indicator of hemolysis). These two tests were significantly increased in controls (P<0.05) but not in the Robuvit® group. Robuvit® supplementation improved training, results and decreased hemolysis.
Collapse
Affiliation(s)
- M G Vinciguerra
- Scienze Motorie DISCAB, Università degli Studi di L'Aquila, Coppito II, Coppito, L'Aquila, Italy -
| | | | | |
Collapse
|
29
|
Belcaro G, Cornelli U, Luzzi R, Ledda A, Cacchio M, Saggino A, Cesarone MR, Dugall M, Feragalli B, Hu S, Pellegrini L, Ippolito E. Robuvit® (Quercus robur extract) supplementation in subjects with chronic fatigue syndrome and increased oxidative stress. A pilot registry study. J Neurosurg Sci 2015; 59:105-117. [PMID: 25394351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM The aim of this registry study was to evaluate the effects of supplementation with Robuvit® (French Quercus robur extract) capsules in subjects with Chronic Fatigue Syndrome (CFS) associated with an increased oxidative stress. Robuvit is a wood extract from Quercus robur (Horphag Research) used to improve liver dysfunction and chronic fatigue. After excluding any disease, subjects observed a defined management plan to improve CFS. Signs/symptoms had been present for more than 6 months in association with an increase in oxidative stress (measured as plasma free radicals). Blood tests were within normal values. METHODS The registry study included 38 CFS subjects and 42 comparable controls. There were no dropouts in the 4 weeks of follow-up; the subjects were evaluated for a further period of 6 months. The management plan included: improved/increased sleep; reduction/abolition in smoking and alcohol or any other agent that may have affected them; control of diet, increase in dietary proteins; good hydration; rest (1/2-1 h/day) and exercise (at least 30 min/day); planned relaxation time; increased time in open spaces. In the Robuvit® supplementation group 300 mg/day of Robuvit® was used. RESULTS Symptoms improved in both groups with a significantly more important improvement in the supplement group (P<0.05). The single items in the Multidimensional Assessment of Fatigue (MAF) questionnaire were statistically better improved (P<0.05) in the supplement group. A parallel improvement in oxidative stress was observed in the supplemented subjects. In the follow up, at 6 months no organic disease was discovered or disease markers found. CONCLUSION This preliminary registry indicates that supplementation with Robuvit® improves CFS in otherwise healthy subjects with no presence of clinical disease or risk conditions. The effects of Robuvit® in CFS may be partially mediated by a clear reduction of plasma free radicals and oxidative stress.
Collapse
Affiliation(s)
- G Belcaro
- Irvine3 Circulation/Vascular Labs, Chieti‑Pescara University, Pescara, Italy, Irvine3 Circulaion Sciences Network
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Mazzatenta A, Pokorski M, Di Tano A, Cacchio M, Di Giulio C. Influence of Sensory Stimulation on Exhaled Volatile Organic Compounds. Adv Exp Med Biol 2015; 884:75-9. [PMID: 26453064 DOI: 10.1007/5584_2015_176] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The real-time exhaled volatile organic compounds (VOCs) have been suggested as a new biomarker to detect and monitor physiological processes in the respiratory system. The VOCs profile in exhaled breath reflects the biochemical alterations related to metabolic changes, organ failure, and neuronal activity, which are, at least in part, transmitted via the lungs to the alveolar exhaled breath. Breath analysis has been applied to investigate cancer, lung failure, and neurodegenerative diseases. There are by far no studies on the real-time monitoring of VOCs in sensory stimulation in healthy subjects. Therefore, in this study we investigated the breath parameters and exhaled VOCs in humans during sensory stimulation: smell, hearing, sight, and touch. Responses sensory stimulations were recorded in 12 volunteers using an iAQ-2000 sensor. We found significant effects of sensory stimulation. In particular, olfactory stimulation was the most effective stimulus that elicited the greatest VOCs variations in the exhaled breath. Since the olfactory pathway is distinctly driven by the hypothalamic and limbic circuitry, while other senses project first to the thalamic area and then re-project to other brain areas, the findings suggest the importance of olfaction and chemoreception in the regulation lung gas exchange. VOCs variations during sensory activation may become putative indicators of neural activity.
Collapse
|
31
|
Mazzatenta A, De Luca C, Di Tano A, Cacchio M, Di Giulio C, Pokorski M. Swelling of Erectile Nasal Tissue Induced by Human Sexual Pheromone. Adv Exp Med Biol 2015; 885:25-30. [PMID: 26820728 DOI: 10.1007/5584_2015_190] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Most chemically mediated sexual communication in humans remains uncharacterized. Yet the study of sexual communication is decisive for understanding sexual behavior and evolutive mechanisms in our species. Here we provide the evidence to consider 4,16-androstadien-3-one (AND) as a man's sexual pheromone. Our experiment provides support for the physiological effect of AND on nasal airway resistance (Rna) in women, as assessed by anterior rhinomanometry. We found that AND administration increased the area of turbinate during the ovulatory phase, resulting in an increase of Rna. Thus, we discovered that minute amounts of AND, acting through neuroendocrine brain control, regulate Rna and consequently affect the sexual physiology and behavior. Fascinatingly, this finding provides the evidence of the preservation of chemosexual communication in humans, which it has been largely neglected due to its unconscious perception and concealed nature. Therefore, chemical communication is a plesiomorphic evolutive phenomenon in humans.
Collapse
Affiliation(s)
- Andrea Mazzatenta
- Physiology and Physiopathology Section, Department of Neuroscience, Imaging and Clinical Science, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy
| | - C De Luca
- Physiology and Physiopathology Section, Department of Neuroscience, Imaging and Clinical Science, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy.,Clinica Villa del Sole, Caserta, Italy
| | - A Di Tano
- Physiology and Physiopathology Section, Department of Neuroscience, Imaging and Clinical Science, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy
| | - M Cacchio
- Physiology and Physiopathology Section, Department of Neuroscience, Imaging and Clinical Science, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy
| | - C Di Giulio
- Physiology and Physiopathology Section, Department of Neuroscience, Imaging and Clinical Science, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy
| | - Mieczyslaw Pokorski
- Public Higher Medical Professional School in Opole, 68 Katowicka St., 45-060, Opole, Poland.
| |
Collapse
|
32
|
Luzzi R, Belcaro G, Hu S, Dugall M, Hosoi M, Cacchio M, Ippolito E, Corsi M. Improvement in symptoms and cochlear flow with pycnogenol in patients with Meniere's disease and tinnitus. Minerva Med 2014; 105:245-254. [PMID: 24988090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM The aim of this supplement registry was to evaluate the efficacy of the Pycnogenol® in improving cochlear flow and symptoms in a 6-month follow-up for patients with Meniere's disease (MD), tinnitus and cochlear hypoperfusion. METHODS Main signs/symptoms were considered: Spontaneous vertigo, positional vertigo, hearing loss, tinnitus, pressure in the ear, unsteady gait, associated clinical problems, alterations in daily life. All subjects were managed with the best available management (BM); one group used the supplement Pycnogenol (150 mg/day). Cochlear flow and tinnitus were also evaluated. Out of 120 patients incuded in the registry, 55 used Pycnogenol and 52 (controls) were managed only with BM. RESULTS There was a more significant improvement in all registry items at 3 and 6 months in the Pycnogenol group (P<0.05). The number of lost working days was lower in the Pycnogenol group. At 3 months, 45.4% of subjects using Pycnogenol were completely asymptomatic in comparison with 23.07% of controls. At 6 months 87.3% of the Pycnogenol subjects were asymptomatic compared with 34.6% of controls. Cochlear flow velocity was significantly better (higher flow, higher diastolic component) in the Pycnogenol group (P<0.05). The subjective tinnitus scale decreased in both groups (P<0.05); the decrease was more significant in Pycnogenol subjects (P<0.05) at 3 and 6 months. CONCLUSION Symptoms of Meniere's disease, flow at cochlear level and tinnitus improved in Pycnogenol subjects in comparison with best management.
Collapse
Affiliation(s)
- R Luzzi
- IRVINE3 Vascular/Circulation Labs Deparment of Biomedical Sciences CH-PE University, Pescara, Italy -
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Di Loreto S, Falone S, D'Alessandro A, Santini S, Sebastiani P, Cacchio M, Amicarelli F. Regular and moderate exercise initiated in middle age prevents age-related amyloidogenesis and preserves synaptic and neuroprotective signaling in mouse brain cortex. Exp Gerontol 2014; 57:57-65. [PMID: 24835196 DOI: 10.1016/j.exger.2014.05.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Revised: 04/24/2014] [Accepted: 05/05/2014] [Indexed: 12/16/2022]
Abstract
Although the beneficial responses induced in the central nervous system by early-initiated exercise have been broadly investigated, the effects of a chronic and moderate lately-initiated exercise on biochemical hallmarks of very early brain senescence have not been extensively studied. We previously reported that a midlife-initiated regimen of moderate running was able not only to prevent the age-related decay of antioxidative and detoxification functions in mouse brain cortex, but also to preserve neurotrophic support and molecular integrity. On this basis, this work investigated whether and how a 2-mo or 4-mo midlife-initiated running protocol could affect the activity of those systems involved in maintaining neuronal function and in preventing the onset of neurodegeneration within the brain cortex of middle-aged CD-1 mice. In particular, we analyzed the production of the peptide amyloid-β and the expression of synapsin Ia, which is known to play a key role in neurotransmission and synaptic plasticity. In addition, we studied the expression of sirtuin 3, as a protein marker of neuroprotection against age-dependent mitochondrial dysfunction, as well as the pro-death pathway induced by proBDNF through the interaction with p75NTR and the co-receptor sortilin. The midlife-initiated 4-mo running program triggered multiple responses within the mouse brain cortex, through the activation of anti-amyloidogenic, pro-survival, synaptogenic and neuroprotective pathways. However, most of the beneficial actions of the exercise regimen appeared only after 4months, since 2-mo-exercised mice showed marked impairments of the endpoints we considered. This could imply that a midlife-initiated regimen of moderate treadmill running may require an adequate time lag to activate beneficial compensative mechanisms within the mouse brain cortex.
Collapse
Affiliation(s)
- Silvia Di Loreto
- Institute of Translational Pharmacology (IFT), National Research Council (CNR), Via Giosuè Carducci, 32 - Rotilio Center, L'Aquila (AQ), Italy
| | - Stefano Falone
- Dept. of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito, L'Aquila (AQ), Italy.
| | - Antonella D'Alessandro
- Dept. of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito, L'Aquila (AQ), Italy
| | - Silvano Santini
- Dept. of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito, L'Aquila (AQ), Italy
| | - Pierluigi Sebastiani
- Institute of Translational Pharmacology (IFT), National Research Council (CNR), Via Giosuè Carducci, 32 - Rotilio Center, L'Aquila (AQ), Italy
| | - Marisa Cacchio
- Dept. of Biomedical Sciences, University "G. d'Annunzio", Via dei Vestini, Chieti Scalo (CH), Italy
| | - Fernanda Amicarelli
- Institute of Translational Pharmacology (IFT), National Research Council (CNR), Via Giosuè Carducci, 32 - Rotilio Center, L'Aquila (AQ), Italy; Dept. of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio-Coppito, L'Aquila (AQ), Italy
| |
Collapse
|
34
|
Vinciguerra G, Belcaro G, Bonanni E, Cesarone MR, Rotondi V, Ledda A, Hosoi M, Dugall M, Cacchio M, Cornelli U. Evaluation of the effects of supplementation with Pycnogenol® on fitness in normal subjects with the Army Physical Fitness Test and in performances of athletes in the 100-minute triathlon. J Sports Med Phys Fitness 2013; 53:644-654. [PMID: 24247188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM The aim of this registry study was to evaluate the effects of Pycnogenol® (French pine bark extract) on improving physical fitness (PF) in normal individuals using the Army Physical Fitness Test (APFT). The study evaluated the efficacy of Pycnogenol, used as a supplement, in improving training, exercise, recovery and oxidative stress. METHODS The study was divided into 2 parts. In PART 1 (Pycnogenol 100 mg/day), the APFT was used to assess an improvement in PF during an 8-week preparation and training program. In PART 2 (Pycnogenol 150 mg/day), the study evaluated the effects of Pycnogenol supplementation in athletes in training for a triathlon. RESULTS PART 1. There was a significant improvement in both males and females in the 2-mile running time within both groups, but the group using Pycnogenol (74 subjects) performed statistically better than controls (73 subjects). The number of push-ups was improved, with Pycnogenol subjects performing better. Sit-ups also improved in the Pycnogenol group. Oxidative stress decreased with exercise in all subjects; in Pycnogenol subjects the results were significantly better. PART 2. In the Pycnogenol group 32 males (37.9; SD 4.4 years) were compliant with the training plan at 4 weeks. In controls there were 22 subjects (37.2;3.5) completing the training plans. The swimming, biking and running scores in both groups improved with training. The Pycnogenol group had more benefits in comparison with controls. The total triathlon time was 89 min 44 s in Pycnogenol subjects versus 96 min 5 s in controls. Controls improved their performing time on average 4.6 minutes in comparison with an improvement of 10.8 minutes in Pycnogenol subjects. A significant decrease in cramps and running and post-running pain was seen in the Pycnogenol group; there were no significant differences in controls. There was an important, significant post-triathlon decrease of PFR one hour after the end of the triathlon with an average of -26.7, whereas PFR in controls increased. In Pycnogenol subjects there was a lower increase on oxidative stress with a faster recovery to almost normal levels (<330 for these subjects). These variations in PFR values were interpreted as a faster metabolic recovery in subjects using Pycnogenol. CONCLUSION This study opens an interesting new application of the natural supplementation with Pycnogenol that, with proper hydration, good training and nutritional attention may improve training and performances both in normal subjects and in semi-professional athletes performing at high levels in difficult, high-stress sports such as the triathlon.
Collapse
Affiliation(s)
- G Vinciguerra
- Irvine 3 International Circulation Vascular Labs & San Val. Epidemiology Department of Biomedical Sciences Chieti‑Pescara University, Pescara, Italy -
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Bottari A, Belcaro G, Ledda A, Cesarone MR, Vinciguerra G, Di Renzo A, Stuard S, Dugall M, Pellegrini L, Errichi S, Gizzi G, Ippolito E, Ricci A, Cacchio M, Ruffini I, Fano F, Hosoi M. Lady Prelox® improves sexual function in post-menopausal women. Panminerva Med 2012; 54:3-9. [PMID: 23241929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM The aim of this pilot, single-blinded study was to evaluate the efficacy of a proprietary, dietary supplement Lady Prelox® for supporting and improving sexual function in generally healthy, post-menopausal women. METHODS The Lady Prelox® and placebo control groups were comparable at inclusion with regard to the total Female Sexual Function Index (FSFI) score, as well as for the six individual FSFI domains, with 40 women (50.1 ± 3.1 years) and 43 women (51.2 ± 2.3 years), respectively. RESULTS At baseline the women in the verum group presented with a mean total FSFI score of 44.6 ± 24.1 which increased significantly already after four weeks treatment with Lady Prelox® to 70.9 ± 18.5 and further increased to 71.7 ± 23.9 after completion of the eight-week trial period. In the control group the mean total FSFI was 44.1 ± 22.8 at inclusion and non-significantly increased to 45 ± 21.4 after four weeks and 47.4 ± 21.8 after eight weeks, respectively. The treatment with Lady Prelox® was comparatively significantly more effective than placebo after both four and eight weeks of treatment (P<0.05). The individual six FSFI domains related to desire, arousal, lubrication, orgasm, satisfaction and pain did all respond favourably to treatment with Lady Prelox®; however, with only marginable higher scores in the placebo group. Four women in each group dropped out because of inabilities to attend scheduled check-ups. No adverse effects were reported. CONCLUSION This study opens an interesting perspective for women experiencing moderate sexual function impairment and suggests a promising new treatment option. Further studies with larger numbers of women, including also premenopausal and perimenopausal women are warranted.
Collapse
Affiliation(s)
- A Bottari
- Irvine3 Circulation-Vascular Labs, Department of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Bottari A, Belcaro G, Ledda A, Cesarone MR, Vinciguerra G, Di Renzo A, Stuard S, Dugall M, Pellegrini L, Errichi S, Gizzi G, Ippolito E, Ricci A, Cacchio M, Ruffini I, Fano F, Hosoi M. Lady Prelox® improves sexual function in post-menopausal women. Panminerva Med 2012:R41122759. [PMID: 23138717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM:he aim of this pilot, single-blinded study was to evaluate the efficacy of a proprietary, dietary supplement Lady Prelox® for supporting and improving sexual function in generally healthy, post-menopausal women. METHODS: The Lady Prelox® and placebo control groups were comparable at inclusion with regard to the total Female Sexual Function Index (FSFI) score, as well as for the six individual FSFI domains, with 40 women (50.1±3.1 years) and 43 women (51.2±2.3 years), respectively. RESULTS:At baseline the women in the verum group presented with a mean total FSFI score of 44.6±24.1 which increased significantly already after four weeks treatment with Lady Prelox® to 70.9±18.5 and further increased to 71.7±23.9 after completion of the eight-week trial period. In the control group the mean total FSFI was 44.1±22.8 at inclusion and non-significantly increased to 45±21.4 after four weeks and 47.4±21.8 after eight weeks, respectively. The treatment with Lady Prelox® was comparatively significantly more effective than placebo after both four and eight weeks of treatment (P<0.05). The individual six FSFI domains related to desire, arousal, lubrication, orgasm, satisfaction and pain did all respond favourably to treatment with Lady Prelox®; however, with only marginable higher scores in the placebo group. Four women in each group dropped out because of inabilities to attend scheduled check-ups. No adverse effects were reported. CONCLUSION: This study opens an interesting perspective for women experiencing moderate sexual function impairment and suggests a promising new treatment option. Further studies with larger numbers of women, including also premenopausal and perimenopausal women are warranted.
Collapse
Affiliation(s)
- A Bottari
- Irvine3 Circulation-Vascular Labs, Department of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy -
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Falone S, D'Alessandro A, Mirabilio A, Cacchio M, Di Ilio C, Di Loreto S, Amicarelli F. Late-onset running biphasically improves redox balance, energy- and methylglyoxal-related status, as well as SIRT1 expression in mouse hippocampus. PLoS One 2012; 7:e48334. [PMID: 23110231 PMCID: PMC3482192 DOI: 10.1371/journal.pone.0048334] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2012] [Accepted: 09/24/2012] [Indexed: 01/20/2023] Open
Abstract
Despite the active research in this field, molecular mechanisms underlying exercise-induced beneficial effects on brain physiology and functions are still matter of debate, especially with regard to biological processes activated by regular exercise affecting the onset and progression of hippocampal aging in individuals unfamiliar with habitual physical activity. Since such responses seem to be mediated by changes in antioxidative, antiglycative and metabolic status, a possible exercise-induced coordinated response involving redox, methylglyoxal- and sirtuin-related molecular networks may be hypothesized. In this study, hippocampi of CD1 mice undergoing the transition from mature to middle age were analyzed for redox-related profile, oxidative and methylglyoxal-dependent damage patterns, energy metabolism, sirtuin1 and glyoxalase1 expression after a 2- or 4-mo treadmill running program. Our findings suggested that the 4-mo regular running lowered the chance of dicarbonyl and oxidative stress, activated mitochondrial catabolism and preserved sirtuin1-related neuroprotection. Surprisingly, the same cellular pathways were negatively affected by the first 2 months of exercise, thus showing an interesting biphasic response. In conclusion, the duration of exercise caused a profound shift in the response to regular running within the rodent hippocampus in a time-dependent fashion. This research revealed important details of the interaction between exercise and mammal hippocampus during the transition from mature to middle age, and this might help to develop non-pharmacological approaches aimed at retarding brain senescence, even in individuals unfamiliar with habitual exercise.
Collapse
Affiliation(s)
- Stefano Falone
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila (AQ), Italy
| | | | - Alessandro Mirabilio
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila (AQ), Italy
| | - Marisa Cacchio
- Department of Basic and Applied Medical Sciences, University “G. d'Annunzio”, Chieti Scalo (CH), Italy
| | - Carmine Di Ilio
- Department of Biomedical Sciences, University “G. d'Annunzio”, Chieti Scalo (CH), Italy
| | - Silvia Di Loreto
- Institute of Translational Pharmacology (IFT) – National Research Council (CNR), L'Aquila (AQ), Italy
| | - Fernanda Amicarelli
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila (AQ), Italy
- * E-mail:
| |
Collapse
|
38
|
Stuard S, Cesarone MR, Belcaro G, Dugall M, Ledda A, Cacchio M, Ricci A, Ippolito E, Di Renzo A, Grossi MG. Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects. Int J Angiol 2012; 17:143-8. [PMID: 22477419 DOI: 10.1055/s-0031-1278299] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
Chronic venous insufficiency (CVI), and related signs and symptoms of venous and diabetic microangiopathy, can be effectively treated with O-(β-hydroxyethyl)-rutosides (HR). The aim of the present independent registry study was to evaluate HR in a long-term (five-year) period of administration that examined the tolerability and safety of HR. Patients with severe CVI and venous microangiopathy were included in the registry. Subjects who completed five years of treatment were considered in the analysis. Blood parameters, liver and renal function tests, microalbuminuria (in diabetic patients) and cholesterol levels were evaluated to assess the effects of HR treatment. Four groups were studied - group A (98 patients) received oral HR (1500 mg per day), group B (87 diabetic patients with CVI) was treated with 2 g of HR per day, group C (90 controls, including 42 diabetic patients) had no pharmacological treatment and group D (113 patients, including 48 diabetic patients) used elastic stockings. No significant negative changes in blood parameters were recorded at two and five years. Decreases in microalbuminuria and total cholesterol, and an increase in high-density lipoprotein cholesterol were observed in HR-treated patients, particularly in diabetic patients. Minimal (nonsignificant) variations were observed in the groups that did not use HR. In conclusion, HR treatment is safe, and some positive effects from HR on cholesterol levels and microalbuminuria (in diabetic patients) that were previously observed may suggest potential new clinical applications.
Collapse
Affiliation(s)
- S Stuard
- Unitá Operative Dialisi/Diaferesi, L'Aquila
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Falone S, D'Alessandro A, Mirabilio A, Petruccelli G, Cacchio M, Di Ilio C, Di Loreto S, Amicarelli F. Long term running biphasically improves methylglyoxal-related metabolism, redox homeostasis and neurotrophic support within adult mouse brain cortex. PLoS One 2012; 7:e31401. [PMID: 22347470 PMCID: PMC3275619 DOI: 10.1371/journal.pone.0031401] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2011] [Accepted: 01/08/2012] [Indexed: 12/15/2022] Open
Abstract
Oxidative stress and neurotrophic support decline seem to be crucially involved in brain aging. Emerging evidences indicate the pro-oxidant methylglyoxal (MG) as a key player in the age-related dicarbonyl stress and molecular damage within the central nervous system. Although exercise promotes the overproduction of reactive oxygen species, habitual exercise may retard cellular aging and reduce the age-dependent cognitive decline through hormetic adaptations, yet molecular mechanisms underlying beneficial effects of exercise are still largely unclear. In particular, whereas adaptive responses induced by exercise initiated in youth have been broadly investigated, the effects of chronic and moderate exercise begun in adult age on biochemical hallmarks of very early senescence in mammal brains have not been extensively studied. This research investigated whether a long-term, forced and moderate running initiated in adult age may affect the interplay between the redox-related profile and the oxidative-/MG-dependent molecular damage patterns in CD1 female mice cortices; as well, we investigated possible exercise-induced effects on the activity of the brain derived neurotrophic factor (BDNF)-dependent pathway. Our findings suggested that after a transient imbalance in almost all parameters investigated, the lately-initiated exercise regimen strongly reduced molecular damage profiles in brains of adult mice, by enhancing activities of the main ROS- and MG-targeting scavenging systems, as well as by preserving the BDNF-dependent signaling through the transition from adult to middle age.
Collapse
Affiliation(s)
- Stefano Falone
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy
- Department of Biomedical Sciences, University “G. d'Annunzio”, Chieti Scalo, Italy
| | | | - Alessandro Mirabilio
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy
| | - Giacomo Petruccelli
- Department of Basic and Applied Medical Sciences, University “G. d'Annunzio”, Chieti Scalo, Italy
| | - Marisa Cacchio
- Department of Basic and Applied Medical Sciences, University “G. d'Annunzio”, Chieti Scalo, Italy
| | - Carmine Di Ilio
- Department of Biomedical Sciences, University “G. d'Annunzio”, Chieti Scalo, Italy
| | - Silvia Di Loreto
- Institute of Translational Pharmacology, National Research Council, L'Aquila, Italy
| | - Fernanda Amicarelli
- Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy
- * E-mail:
| |
Collapse
|
40
|
Grossi MG, Belcaro G, Cesarone MR, Dugall M, Hosoi M, Cacchio M, Ippolito E, Bavera P. Improvement in cochlear flow in patients with tinnitus with the complex supplement Acustop: a product evaluation. Panminerva Med 2011; 53:89-93. [PMID: 22108483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIM Patients with tinnitus constitute a very large group without a real, specific therapeutic solution. With noninvasive, color duplex it is possible to measure flow in the cochlear artery and to follow duplex flow changes due to treatments in most patients. The aim of this preliminary evaluation was to study flow variations in patients with "mild-to-moderate" tinnitus, possibly associated to cochlear hypo-perfusion, after administration of Acustop (used as a food supplement). The aim was to improve cochlear flow decreasing the level of tinnitus. METHODS Patients with "mild-to-moderate", "idiopathic", monolateral tinnitus, present for at least 4 weeks were included; no vertigo or important hearing loss had been observed. The origin of tinnitus had been sudden (hours or days). The tinnitus was associated to a decrease in cochlear flow measured by color Duplex at the affected ear. A group of 42 patients was evaluated; 25 used Acustop; there were 17 controls (follow-up only). Groups were comparable for their clinical problem and other details. The average duration of treatment was 4 weeks. RESULTS No side effects were observed and no drop-outs were recorded. Flow velocity at the level of the affected inner ear was significantly lower (both the diastolic and systolic components; P<0.05) in comparison with the other ear. This was considered an indication of the vascular origin of the tinnitus. With Acustop treatment there was a significant improvement in systolic (P<0.05) and diastolic flow velocity (P<0.05). The increase in flow velocity was not significant in controls. An analogue scale line was used to measure symptoms in the Acustop group: it was 8.2;2 at inclusion; it decreased to 3.1;1.5 at 4 weeks (P<0.05). The score was 8.4;2 in controls at inclusion; at 4 weeks the score was 7.1;2.2 (not significant). Tinnitus scale: the value at inclusion of the tinnitus scale in the Acustop group a was 8.5;1.1 versus 8.3;1.2 in controls. After 4 weeks the score was 3.1;1.1 (P<0.05) in the Acustop group vs 7.2 in controls; the difference between the two groups was significant; P<0.025). CONCLUSION In conclusion, these results suggest that in selected patients with tinnitus and altered inner ear perfusion Acustop appears to be effective in relieving tinnitus possibly by improving cochlear flow. More studies should be planned to evaluate better the potential applications of Acustop in this very interesting field. This clinical problem affects a large number of patients, without a real therapeutic solution at the moment, decreasing their quality of life and their performing abilities.
Collapse
Affiliation(s)
- M G Grossi
- Irvine3 Labs, Department of Biomedical Sciences Chieti - Pescara University, Pescara, Italy
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Ippolito E, Fano F, Dugall M, Cacchio M, Di Renzo A, Hosoi M, Stuard S, Corsi M. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine 2010; 17:835-839. [PMID: 20579863 DOI: 10.1016/j.phymed.2010.04.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2009] [Revised: 03/03/2010] [Accepted: 04/26/2010] [Indexed: 05/29/2023]
Abstract
The aim of this study was to evaluate the clinical efficacy of standardized French maritime pine bark extract Pycnogenol in patients with severe chronic venous insufficiency (CVI). 98 subjects with symptomatic CVI and edema were randomly assigned to one group treated with 150 mg Pycnogenol a day only, another group with stockings only and a third group with both Pycnogenol and elastic stockings. The average ambulatory venous pressure (AVP) at inclusion was 58+/-7 mm Hg (range 48-60 mm Hg) with a refilling time (RT)<12 s (average 7+/-2 s). The duration of the disease was on average 6.0+/-3.1 years. There were no differences in AVP or RT among the 3 groups at inclusion and microcirculatory and clinical evaluations were comparable. After 8 weeks treatment there was a significant decrease of rate of ankle swelling, resting flux, transcutaneous pO(2) and clinical symptom scores in all groups with significantly better results for the combination treatment. Pycnogenol alone was more effective than compression alone for all parameters (p<0.05). No side-effects were observed; compliance and tolerability were very good. This study corroborates a significant clinical role for Pycnogenol in the management, treatment and control of CVI also in combination with compression.
Collapse
Affiliation(s)
- M R Cesarone
- Department of Biomedical Sciences, G D'Annunzio, Chieti-Pescara University, Faculty of Motory Sciences, L'Aquila University, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Falone S, Mirabilio A, Pennelli A, Cacchio M, Di Baldassarre A, Gallina S, Passerini A, Amicarelli F. Differential impact of acute bout of exercise on redox- and oxidative damage-related profiles between untrained subjects and amateur runners. Physiol Res 2010; 59:953-961. [PMID: 20533869 DOI: 10.33549/physiolres.931884] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Despite the demonstrated exercise-induced increase in reactive oxygen species (ROS) production, growing epidemiological evidence indicates that habitual, moderate physical activity reduces the incidence of several oxidative stress-based diseases. This apparent paradox can be explained taking into account that ROS produced during repeated exercise bouts may act as mild stressors able to trigger physiological and biomolecular hormetic responses through a number of redox-sensitive transcription pathways. Unfortunately, much more limited information is available from general population-based research, which could better reflect the condition of common people interested in achieving and maintaining good fitness levels. The present work aimed at investigating whether and how exercise-related habits in non-professional regular runners (n=33) can affect the systemic anti-oxidative capacity, and the resting serum levels of typical lipid peroxidation-related by-products and oxidatively-damaged proteins, in comparison with untrained sedentary individuals (n=25). We also analyzed in both groups the redox response elicited by a modified Bruce-based maximal exercise test on the same parameters. Our findings indicated that long-term regular and moderate practice of aerobic physical activity can increase antioxidant defense systems, lower the resting protein oxidation processes and reduce the immediate up-regulation of lipid-targeting oxidative stress in response to an acute bout of exercise.
Collapse
Affiliation(s)
- S Falone
- Department of Biomedical Sciences, University G. d’Annunzio of Chieti-Pescara, Chieti Scalo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Grossi MG, Belcaro G, Cesarone MR, Dugall M, Hosoi M, Cacchio M, Ippolito E, Bavera P. Improvement in cochlear flow with Pycnogenol® in patients with tinnitus: a pilot evaluation. Panminerva Med 2010; 52:63-67. [PMID: 20657537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
AIM The aim of this preliminary evaluation was to study the efficacy of Pycnogenol in improving cochlear flow in patients with mild-to-moderate tinnitus present for at least two weeks (without vertigo or important hearing loss), possibly associated with cochlear hypo-perfusion. METHODS Patients with mild-to-moderate, idiopatic, monolateral tinnitus present for at least 2 weeks were included; no vertigo or important hearing loss had been found in a specific examination. The origin of tinnitus had been sudden (hours or days). Fifty-eight patients used Pycnogenol: 24 used 150 mg/day (group A; mean age 43.2+/-4.3) and 34 patients 100 mg/day (group B: mean age 42.4+/-3.8). Controls included 24 patients (mean age 42.3+/-4.5). The groups were comparable for their clinical problem and age and sex. The average duration of treatment was 34.3+/-3.1 days. No side effects were observed and no drop-outs occurred. RESULTS The variations in cochlear flow velocity (in cm/s at the cochlear artery), at inclusion and after four weeks of treatment indicated that flow velocity at the level of the affected ear was significantly lower (both the diastolic and systolic components; P<0.05) in comparison with the other ear. The treatment favored an improvement in systolic (P<0.05) and diastolic flow velocity (P<0.05) in the two treatment groups A+B. The increase in flow velocity was very limited and not significant in controls. CONCLUSION These results suggest that in selected patients with tinnitus and altered perfusion, Pycnogenol is effective in a short period of time in relieving tinnitus symptoms by improving cochlear blood flow. The effect is more pronounced with higher Pycnogenol dosage. More studies should be planned to better evaluate the pathology and potential applications of Pycnogenol in a larger number of patients who are currently without a real therapeutic solution.
Collapse
Affiliation(s)
- M G Grossi
- Irvine3 Labs, Department of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, Dugall M, Cacchio M, Schönlau F. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther 2010; 25:537-40. [PMID: 19916788 DOI: 10.1089/jop.2009.0023] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE The growing numbers of diabetes cases in the developed world are followed by increasing numbers of people diagnosed with diabetic complications. Diabetic microangiopathies in the eye lead to the development of retinopathy involving gradual loss of vision. Previous studies with Pycnogenol showed effectiveness for stopping progression of preproliferative stages of retinopathy. The aim of our study was to show protective effects of Pycnogenol in early stages of retinopathy, characterized by mild to moderate retinal edema in the absence of hemorrhages or hard exudates in the macula center. METHODS Following treatment with Pycnogenol (24 patients) for 3 months, retinal edema score (dilated ophthalmology) and retinal thickness (high resolution ultrasound) showed statistically significant improvement as compared to the placebo group (22 patients), which showed negligible changes to baseline. Laser Doppler flow velocity measurements at the central retinal artery showed a statistically significant increase from 34 to 44 cm/s in the Pycnogenol group as compared to marginal effects in the control group. RESULTS The major positive observation of this study is the visual improvement, which was subjectively perceived by 18 out of 24 patients in the Pycnogenol group. Testing of visual acuity using the Snellen chart showed a significant improvement from baseline 14/20 to 17/20 already, after 2 months treatment, whereas no change was found in the control group. CONCLUSIONS Pycnogenol taken at this early stage of retinopathy may enhance retinal blood circulation accompanied by regression of edema, which favorably improves vision of patients.
Collapse
Affiliation(s)
- Robert Steigerwalt
- Irvine2 Vascular Labs and Microcirculation, Physiology, Department of Biomedical Sciences, G D'Annunzio University, General Surgery, Guardiagrele (Ch)-Ortona (Pe) Pescara, San Valentino Vascular Screening Project, San Valentino, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Falone S, Mirabilio A, Passerini A, Izzicupo P, Cacchio M, Gallina S, Baldassarre AD, Amicarelli F. Aerobic Performance and Antioxidant Protection in Runners. Int J Sports Med 2010. [DOI: 10.1055/s-0030-1250772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Cesarone MR, Belcaro G, Stuard S, Schönlau F, Di Renzo A, Grossi MG, Dugall M, Cornelli U, Cacchio M, Gizzi G, Pellegrini L. Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants--a controlled study. J Cardiovasc Pharmacol Ther 2010; 15:41-6. [PMID: 20097689 DOI: 10.1177/1074248409356063] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
This study evaluated the effects of Pycnogenol as an adjunct to angiotensin-converting enzyme (ACE)-inhibitor ramipril treatment of hypertensive patients presenting with early signs of renal function problems. One group of 26 patients was medicated with 10 mg ramipril per day only; a second group of 29 patients took Pycnogenol in addition to the ACE inhibitor over a period of 6 months. At trial end, a lowered systolic and diastolic blood pressure was found in both groups, with a significant further reduction of diastolic pressure in the group given Pycnogenol in addition to ramipril. The major aim of this study was the investigation of kidney-protective effects of Pycnogenol. Urinary albumin decreased from 87 +/- 23 to 64 +/- 16 mg/d with ramipril only. Additional Pycnogenol lowered albumin significantly better from 91 +/- 25 to 39 +/- 13 mg/day (P < .05). In both groups, serum creatinine was lowered; however, only in the combination treatment group did the effect reached statistical significance. In both groups, CRP levels decreased from 2.1 to 1.8 with ramipril and from 2.2 to 1.1 with the ramipril-Pycnogenol combination; the latter reached statistical significance. Kidney cortical flow velocity was investigated by Doppler color duplex ultrasonography. Both systolic and diastolic flow velocities increased significantly after 6 months medication with ramipril. The addition of Pycnogenol to the regimen statistically significantly further enhanced kidney cortical flow velocities, by 8% for diastolic flow and 12% for systolic flow, relative to values found for the group taking ramipril only. The protective effects of Pycnogenol for initial kidney damage found in this study warrant further research with a larger number of patients and over a longer period of time.
Collapse
Affiliation(s)
- Maria Rosaria Cesarone
- Irvine3, Vascular Labs & Microcirculation, Physiology, Department of Biomedical Sciences, G D'Annunzio University, Pescara, San Valentino Vascular Screening Project, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Belcaro G, Cesarone MR, Errichi B, Di Renzo A, Grossi MG, Ricci A, Dugall M, Cornelli U, Cacchio M, Rohdewald P. Pycnogenol®
treatment of acute hemorrhoidal episodes. Phytother Res 2009; 24:438-44. [DOI: 10.1002/ptr.3021] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
48
|
Falone S, Mirabilio A, Passerini A, Izzicupo P, Cacchio M, Gallina S, Baldassarre AD, Baldassarre AD, Amicarelli F. Aerobic performance and antioxidant protection in runners. Int J Sports Med 2009; 30:782-8. [PMID: 19685417 DOI: 10.1055/s-0029-1233464] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Reactive oxygen species (ROS) production is known to increase as a result of muscular contractile activity and this phenomenon may perturb the fine-controlled cellular redox homeostasis within cells and tissues. We studied the possible correlations between individual aerobic performance-related factors and the oxidative stress markers profile in the serum of thirty-five endurance male runners that experienced a modified Bruce-based maximal graded exercise test. Our investigation assessed the systemic levels of malondialdehyde (MDA), protein carbonyl content (PCC) and total antioxidant status (TAS). We found that redox-related parameters and aerobic performance indicators were correlated. Indeed, significant negative associations between TAS and PCC (r-value -0.7, p<0.001) and between TAS and total protein content (r-value -0.4, p=0.005) were observed. A significant positive association between total protein and PCC (r-value 0.4, p=0.012) was also revealed. Only a trend of negative correlation between serum total protein and anaerobic threshold (r-value -0.3, p=0.07) was found. Interestingly, different responses in MDA levels were elicited by the ergometric test as a function of the individual anaerobic threshold. High aerobic capacities may be promising anthropometric factors indicative of adapted biochemical environments featuring enhanced protection against the oxidative challenge elicited by both regular endurance training and single intense exercise bouts.
Collapse
Affiliation(s)
- S Falone
- University G. d'Annunzio, Department of Biomedical Sciences, Chieti, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, Ledda A, Di Renzo A, Stuard S, Dugall M, Pellegrini L, Gizzi G, Ippolito E, Ricci A, Cacchio M, Cipollone G, Ruffini I, Fano F, Hosoi M, Rohdewald P. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep 2009; 13:271-6. [PMID: 19017467 DOI: 10.1179/135100008x309019] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
In a previous, double-blind, placebo-controlled study we evaluated the efficacy of a 3-month treatment with Pycnogenol for 156 patients with osteoarthritis of the knee. Pycnogenol significantly decreased joint pain and improved joint function as evaluated using the WOMAC score and walking performance of patients on a treadmill. In this study, we further investigated the anti-inflammatory and antioxidant activity of Pycnogenol in a subset of the osteoarthritis patients presenting with elevated C-reactive protein (CRP) and plasma-free radicals. Elevated CRP levels have been suggested to be associated with disease progression in osteoarthritis. In our study, 29 subjects of the Pycnogenol group and 26 patients in the placebo group showed CRP levels higher than 3 mg/l at baseline. Comparison of blood specimens drawn at baseline and after 3-month treatment showed that Pycnogenol significantly decreased plasma free radicals to 70.1% of baseline values. Plasma CRP levels decreased from baseline 3.9 mg/l to 1.1 mg/l in the Pycnogenol group whereas the control group had initial values of 3.9 mg/l which decreased to 3.6 mg/l. The CRP decrease in the Pycnogenol was statistical significant as compared to the control group (P < 0.05). Fibrinogen levels were found to be lowered to 62.8% of initial values (P < 0.05) in response to Pycnogenol. No significant changes for plasma free radicals, CRP and fibrinogen were found in the placebo-treated group. The decrease of systemic inflammatory markers suggests that Pycnogenol may exert anti-inflammatory activity in osteoarthritic joints and patients did not present with other ailments or infections. The nature of the anti-inflammatory effects of Pycnogenol with regard to CRP warrants further investigation.
Collapse
Affiliation(s)
- G Belcaro
- Westfälische Wilhelms-Universität Münster, Münster, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Di Giulio C, Petruccelli G, Bianchi G, Cacchio M, Verratti V. Does hypoxia cause sarcopenia? Prevention of hypoxia could reduce sarcopenia. J BIOL REG HOMEOS AG 2009; 23:55-58. [PMID: 19321047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Sarcopenia is the physiological age-related reduction of muscle mass and strength. Considering that life span is correlated with metabolic rate and mitochondria are the site of oxygen consumption, muscle mitochondria volume densities were determined by morphometric analysis. We found a tight correlation between aging and hypoxia with decrease in muscle total mitochondria volume. Therefore, hypoxia and aging seem to share some common pathways, allowing hypoxic models to be used for the study of the aging processes. Additional research will be required to fully elucidate the correlations among aging, sarcopenia and hypoxia, but these findings provide a starting point for such investigations.
Collapse
|